Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: Comparison with rheumatoid factor

British Journal of Rheumatology

Volumn 35, Issue 7, 1996, Pages 620-624

  Cordonnier, C ^a   Meyer, O ^a   Palazzo, E ^a   De Bandt, M ^a   Elias, A ^a   Nicaise, P ^a   Haim T ^a   Kahn, M F ^a   Chatellier, G ^b  

^a BICHAT HOSPITAL   (France)

^b HÔPITAL BROUSSAIS   (France)

Author keywords

Anti RA33 antibody; Antikeratin antibody; Antiperinuclear factor; Early rheumatoid arthritis

Indexed keywords

ANTIBODY; ANTINUCLEAR ANTIBODY; ANTIPERINUCLEAR FACTOR; AUTOANTIBODY; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RHEUMATOID FACTOR; STEROID;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POLYARTHRITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SEROLOGY;

EID: 0030013058     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/35.7.620     Document Type: Article

References (24)

1. Arnett F, Edworthy S, Bloch A et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
2. Nienhuis R, Mandema E. A new serum factor in patients with rheumatoid arthritis: the perinuclear factor. Ann Rheum Dis 1964;23:302-5.
3. Young B, Mallya R, Leslie R, Clark C, Hamblin T. Antikeratin antibodies in rheumatoid arthritis. Br Med J 1979;2:97-9.
4. Sebbag M, Simon M, Vincent C et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995;95:2672-9.
5. Hassfeld W, Steiner G, Hartmunth K et al. Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum 1989;32:1515-20.
6. Steiner G, Hartmuth K, Skriner K et al. Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. J Clin Invest 1992;90:1061-6.
7. Del Puente A, Knowler W, Pettit D, Bennett P. The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum 1988;31:1239-44.
8. Hoet R, Van Venrooij W. The antiperinuclear factor (APF) and antikeratin antibodies (AKA) in rheumatoid arthritis. In: Smolen JS, Kalden JR, Maini RN, eds. Rheumatoid arthritis. Berlin: Springer Verlag, 1992: 299-318.
9. Meyer O, Fabregas D, Cyna L, Ryckewaert A. Les anticorps anti-kératine, un marqueur des polyarthrites évolutives. Rev Rhum 1986;53:601-5.
10. Meyer O, Tauxe F, Fabregas D et al. Anti-RA33 antinuclear antibody in rheumatoid arthritis and mixed connective tissue disease: comparison with antikeratin and antiperinuclear antibodies. Clin Exp Rheumatol 1993;11:473-8.
11. Vincent C, Sere G, Lapeyre F et al. High diagnostic value in rheumatoid arthritis of antibodies to the stratum corneum of rat oesophagus epithelium, so called antikeratin antibodies. Ann Rheum Dis 1989;48:712-22.
12. Centor RM. Estimating confidence intervals of likelihood ratios. Med Decision Making 1992;12:229-33.
13. Finals R, Masi A, Larsen R, Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-15.
14. Jaeschke R, Guyatt G, Sackett D. Users' guides to the medical literature. Ill How to use an article about diagnostic test. A. Are the results of the study valid? J Am Med Assoc 1994;271:389-91.
15. Wolfe F, Ross K, Hawley D, Roberts FK, Cathey MA. The prognosis of rheumatoid arthritis and undifferentiated polyarthritis syndrome in the clinic: a study of 1141 patients. J Rheumatol 1993;20:2005-9.
16. Hassfeld W, Steiner G, Graninger W, Witzman G, Schweitzer H, Smolen J. Antibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br J Rheumatol 1993;32:199-203.
17. Kurki P, Von Essen R, Okubo S, Isomali H. Comparison of the predictive value of serological markers in early arthritis. Scand J Rheumatol 1992;21:158.
18. Paimela L, Gripenberg M, Kurki P, Leirisalo-Repo M. Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis. Ann Rheum Dis 1992;51:743-6.
19. Masi A, Maldonado-Cocco J, Kaplan S, Feigenbaum S, Chandler R. Prospective study of the early course of rheumatoid arthritis in young adults: comparison of patients with and without rheumatoid factor positivity at entry and identification of variables correlating with outcome. Semin Arthritis Rheum 1976;5:299-326.
20. Aho K, Palosuit, Raunio V, Puska P, Aromaa A, Salonen T. When does rheumatoid disease start? Arthritis Rheum 1985;28:485-9.
21. Otten H, Westendorp B. Significance of the Waaler-Rose test, streptococcal agglutination, and antistreptolysin titre in the prognosis of rheumatoid arthritis. Ann Rheum Dis 1959;18:24-8.
22. Delbarre F, Renoux M, Weill B. La recherche des facteurs rhumatoïdes, base du diagnostic sérologique de la maladie rhumatoïde. In: Immunopathologie ostéoarticulaire. Paris: Masson, 1983:62-72.
23. Michotte L, Vanslype J. Influence de la chrysothérapie sur le facteur agglutinant dans la polyarthrite chronique évolutive. Rev Rhum 1958;9-10:656-60.
24. Combe B, Eliaou JF, Daures JP, Meyer O, Clot J, Sany J. Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. Br J Rheumatol 1995;34:529-34.